Nadège Vimont

AbolerIS Pharma

Poster(s):

• Tu110 - anti-cd45rc Mab Treatment Improves Experimental Inflammatory Bowel Disease (IBD)
  Tuesday, June 20, 2023

  6:00 PM – 7:45 PM